Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.70 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13153658 | 0.91 | SLC5A2 (0.67) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2858077 | 0.90 | SLC5A2 (0.71) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2868243 | 0.90 | SLC5A2 (0.78) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL12167137 | 0.90 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL22450868 | 0.89 | SLC5A2 (0.72) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1146580 | 0.89 | SLC5A2 (0.72) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2870946 | 0.89 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2874384 | 0.89 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13153655 | 0.89 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2871805 | 0.89 | SLC5A2 (0.64) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557782-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8557782-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8557782-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-15 | — | — | US | disclosed |
| EP-2024352-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INT (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-2382972-A1 | Methods for preventing and treating neurodegenerative disorders | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7776830-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7776830-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20080058379-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058379-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058379-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007128749-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128749-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259821-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259821-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259821-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| WO-2007093610-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007093610-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058379-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | UGGT1, GALE, UGT1A4 | SLC5A2 4/4885SLC5A1 5/4885ADRA2A 2183/4885 |
| US-20070259821-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | UGGT1, UGT1A4, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885ADRA2A 2034/4885 |
| US-20100249392-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | UGGT1, UGT1A4, SLC5A1 | SLC5A2 5/4885SLC5A1 3/4885ADRA2A 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.